Search

The Fellows of the American Association for Cancer Research (AACR) have elected Charles L. Sawyers, MD, chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK), as their President-Elect for 2020–2021.

… Friday, June 12, 2020 The Fellows of the American Association for Cancer Research (AACR) have elected Charles L. Sawyers, MD , chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK), as their President-Elect for 2020–2021. He will assume the presidency

MSK launched the Kravis Women in Science Endeavor (WiSE) in 2020 to pledge a commitment to support gender equity in science. The winners will be recognized at the annual Kravis WiSE Symposium which is held every year during Women’s History Month.

… Wednesday, March 10, 2021 Ms. Regina Bou Puerto and Mijin Kim, PhD Ms. Regina Bou Puerto and Mijin Kim, PhD Memorial Sloan Kettering Cancer Center (MSK) announced that Sloan Kettering Institute (SKI) researchers Regina Bou Puerto and Mijin Kim, PhD , have been named 2021 Marie-Josée Kravis Women in Science

Memorial Sloan Kettering Cancer Center has recruited Sohrab Shah, PhD, to serve as the inaugural Chief of Computational Oncology within the Department of Epidemiology and Biostatistics. In this role, Dr. Shah will lead the effort to build a research program dedicated to harnessing MSK’s numerous “Big Data” resources to translate biologic knowledge to clinical practice.

… Tuesday, April 17, 2018 Memorial Sloan Kettering Cancer Center (MSK) has recruited Sohrab Shah, PhD , to serve as the inaugural Chief of Computational Oncology within the Department of Epidemiology and Biostatistics . In this role, Dr. Shah will lead the effort to build a research program dedicated to

MSK Kids is leading a major effort to fully deliver on the promise of precision medicine for our youngest patients.

… Thursday, October 3, 2019 Rihanna sitting in a chair outside Rihanna before her first birthday. Photo: Ana Plaza MSK Kids pediatric oncologist Neerav “Neal” Shukla Neerav “Neal” Shukla is Director of the Pediatric Translational Medicine Program. Photo: Karsten Moran MSK Kids Chair Andrew Kung MSK Kids

Children, teens, and young adults with leukemia that have stopped responding to chemotherapy are the first eligible to receive the new treatment.

… Wednesday, August 30, 2017 Summary A novel form of immunotherapy called CAR T is now an FDA-approved option for people with acute lymphoblastic leukemia (ALL) that has stopped responding to chemotherapy. Our scientists played several key roles in CAR T cell therapy development. In what is being hailed

Thousands of oncology experts from around the world will tune in May 29-31 for the American Society of Clinical Oncology’s (ASCO) Virtual Scientific Program. MSK physicians and scientists are involved in notable research to be presented at the meeting.

… Wednesday, May 27, 2020 Thousands of oncology experts from around the world will tune in May 29-31 for the American Society of Clinical Oncology’s (ASCO) Virtual Scientific Program . The online meeting will provide an engaging lineup of scheduled and on-demand scientific content including a plenary session

The FDA has granted full approval to the targeted therapy selpercatinib (Retevmo®) for treating thyroid cancers that have certain changes in a gene called RET. Learn about MSK’s role in the development of this drug and about how patients may benefit.

… Wednesday, July 10, 2024 On June 12, 2024, the US Food and Drug Administration (FDA) granted full approval to the targeted therapy  selpercatinib (Retevmo ® ) for treating adult and pediatric patients 2 years and older with advanced or metastatic  thyroid cancers that have certain changes in a gene called

Learn more about the new FDA-approved drug repotrectinib (AugtyroTM), which targets ROS1 fusions in lung cancer and other cancer types.

… Wednesday, January 10, 2024 Ingrid Adams, now 68, has been coping with metastatic lung cancer for more than a decade. Standard treatment — including chemotherapy and radiation therapy — kept her disease under control for a while, but the cancer continued to spread. Everything changed when she came to

Obtenga más información sobre el nuevo fármaco aprobado por la FDA, repotrectinib (AugtyroTM), que ataca las fusiones de ROS1 en el cáncer pulmonar y otros tipos de cáncer.

… Wednesday, January 10, 2024 Ingrid Adams, que ahora tiene 68 años, ha estado lidiando con el cáncer pulmonar metastásico durante más de una década. El tratamiento estándar, que incluye quimioterapia y radioterapia , mantuvo su enfermedad bajo control por un tiempo, pero el cáncer continuó diseminándose

Learn what can be done for patients like Stephanie Soto-Vega who confront financial hardships caused by cancer.

… Thursday, April 10, 2025 It was hard enough for Stephanie Soto-Vega to get the news that her breast cancer had spread to her hip bones and spine. Then came another blow: Her insurance company wouldn’t cover the medication to keep the cancer under control. It cost $15,000 a month. “I was really worried